Related Experiment Video

Updated: Mar 29, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.8K

Clostridium difficile Infection

Kevin J Downes1, Samir S Shah2

  • 1Divisions of Infectious Diseases and.

Journal of the Pediatric Infectious Diseases Society
|December 1, 2015
PubMed

Insights

Clostridium difficile infections are rising in severity and incidence, posing new treatment and prevention challenges. Pediatricians often lack specific guidance for Clostridium difficile management in children, relying on adult data.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Clinical Medicine

Background:

  • Rising incidence and severity of Clostridium difficile infections (CDI) over recent decades.
  • Emerging challenges in treating and preventing both hospital- and community-acquired CDI.
  • Limited specific guidance for pediatric CDI management, necessitating reliance on adult studies.

Purpose of the Study:

  • To provide a synopsis of recent publications on Clostridium difficile infections.
  • To discuss the implications of these findings within pediatric infectious diseases.
  • To address the knowledge gaps in pediatric CDI treatment and prevention.

Main Methods:

  • Review and synopsis of recent scientific publications focusing on Clostridium difficile.
  • Analysis of treatment and prevention strategies for Clostridium difficile infections.
  • Discussion of findings relevant to pediatric populations.

Main Results:

  • Increased incidence and severity of Clostridium difficile infections noted.
  • Treatment and prevention of both hospital- and community-acquired disease present new challenges.
  • Significant unanswered questions remain regarding Clostridium difficile management in children.

Conclusions:

  • Pediatricians require more specific data for Clostridium difficile infection management in children.
  • Recent publications offer insights but highlight the need for further pediatric-focused research.
  • Addressing pediatric Clostridium difficile infections requires tailored approaches beyond adult guidelines.

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.4K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.4K

Related Concept Videos

Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
55
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.5K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
872
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.1K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
32